Concepts (61)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Polymerase III | 9 | 2012 | 28 | 1.090 |
Why?
|
| Gram-Positive Bacteria | 8 | 2012 | 36 | 0.870 |
Why?
|
| Guanine | 3 | 2012 | 23 | 0.550 |
Why?
|
| Anti-Bacterial Agents | 7 | 2012 | 786 | 0.540 |
Why?
|
| Uracil | 5 | 2006 | 30 | 0.250 |
Why?
|
| Aniline Compounds | 4 | 2006 | 36 | 0.240 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2011 | 15 | 0.230 |
Why?
|
| Enterococcus faecalis | 1 | 2003 | 12 | 0.200 |
Why?
|
| DNA Polymerase II | 1 | 2002 | 8 | 0.200 |
Why?
|
| Genes, Bacterial | 1 | 2003 | 121 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 700 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2005 | 769 | 0.170 |
Why?
|
| Enzyme Inhibitors | 3 | 2011 | 373 | 0.170 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 2011 | 12 | 0.160 |
Why?
|
| Bacillus subtilis | 1 | 2012 | 31 | 0.100 |
Why?
|
| DNA Replication | 2 | 2012 | 234 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 129 | 0.090 |
Why?
|
| Purines | 1 | 2011 | 42 | 0.090 |
Why?
|
| Drug Design | 1 | 2012 | 136 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2011 | 34 | 0.090 |
Why?
|
| Morpholines | 1 | 2011 | 89 | 0.090 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 266 | 0.090 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2006 | 8 | 0.080 |
Why?
|
| Structure-Activity Relationship | 5 | 2006 | 369 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2006 | 34 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2011 | 203 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2011 | 708 | 0.050 |
Why?
|
| Guanosine Triphosphate | 1 | 2003 | 50 | 0.050 |
Why?
|
| Staphylococcal Infections | 3 | 2011 | 129 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2002 | 188 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 383 | 0.050 |
Why?
|
| Catalysis | 1 | 2002 | 161 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 406 | 0.040 |
Why?
|
| Staphylococcus aureus | 3 | 2006 | 177 | 0.040 |
Why?
|
| Base Sequence | 1 | 2003 | 1333 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 837 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2003 | 1594 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1992 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 2 | 2006 | 57 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2006 | 90 | 0.030 |
Why?
|
| Vancomycin | 1 | 2011 | 39 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 368 | 0.020 |
Why?
|
| Animals | 4 | 2011 | 20579 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 366 | 0.020 |
Why?
|
| Mice | 3 | 2011 | 10802 | 0.020 |
Why?
|
| Enterococcus | 1 | 2006 | 10 | 0.020 |
Why?
|
| Staphylococcus | 1 | 2006 | 17 | 0.020 |
Why?
|
| Bacillus | 1 | 2006 | 13 | 0.020 |
Why?
|
| Microbial Viability | 1 | 2006 | 58 | 0.020 |
Why?
|
| Toxicity Tests, Acute | 1 | 2006 | 1 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 100 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 573 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 862 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2174 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 764 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 900 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2038 | 0.010 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 260 | 0.010 |
Why?
|
| Humans | 3 | 2011 | 62678 | 0.010 |
Why?
|
| Female | 1 | 2011 | 32488 | 0.010 |
Why?
|
| Male | 1 | 2006 | 29483 | 0.000 |
Why?
|